Normalized Interferon Signatures and Clinical Improvements by IFNAR1 Blocking Antibody (Anifrolumab) in Patients with Type I Interferonopathies

Genia Kretzschmar,Laura Piñero Páez,Ziyang Tan,Jun Wang,Laura Gonzalez,Constantin Habimana Mugabo,Anette Johnsson,Yang Chen,Jaromír Mikeš,Tadepally Lakshmikanth,Anna James,Raphaela Goldbach-Mansky,Marie Fischer,Karin Palmblad,Sara Alehashemi,AnnaCarin Horne,Petter Brodin
DOI: https://doi.org/10.1007/s10875-024-01826-2
IF: 8.542
2024-10-24
Journal of Clinical Immunology
Abstract:A causal role of type-I interferons (IFN-I) in autoinflammatory type-I interferonopathies such as SAVI (STING–associated vasculopathy with onset in infancy) and CANDLE (chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures) is suggested by elevated expression of IFN-I stimulated genes (ISGs). Hitherto, the lack of specific inhibitors of IFN-I signaling has prevented the verification of a causal role for IFN-I in these conditions. Commonly used inhibitors of the JAK/STAT pathway exert broad effects on multiple signaling pathways leading to more general immunosuppression beyond IFN-I signaling.
immunology
What problem does this paper attempt to address?